mounjaro o tirzepatide Compounded vs. It may also help in weight management for people with obesity or overweight Mounjaro is second obesity drug

Reported complications described in some GLP-1 drug claims have included: Severe or persistent gastrointestinal symptoms , such as ongoing nausea, vomiting, or abdominal pain Delayed stomach emptying (gastroparesis) , which has been described by some individuals as involving bloating, nausea, vomiting, or difficulty tolerating food Intestinal complications , including reduced bowel activity (ileus), which may involve abdominal discomfort, cramping, or vomiting Gallbladder-related conditions , such as gallstones or gallbladder inflammation Blood-clot-related conditions , including deep vein thrombosis or pulmonary embolism, described in some reports and legal filings Vision-related problems , including reports involving non-arteritic anterior ischemic optic neuropathy (NAION) discussed in connection with semaglutide in certain contexts Not everyone who takes a GLP-1 medication experiences these issues, and the relationship between GLP-1 drugs and reported complications continues to be evaluated in legal proceedings

The public and the media may see reports of hair loss by some GLP-1 medications and then create social media posts or sensationalized headlines

Your healthcare provider can help you choose a target, but a common starting point is cutting about 500 calories per day

Novo Nordisk gives a monthly list price of $935.77 for Ozempic and a $935.77 list price for Rybelsus